FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

Links shared publicly online about this topic.

  • 917
    total visits

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

news-medical.net

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

View full resource at news-medical.net

Tags: Vaccination, Meningitis, Diet and Nutrition, Children's Health, FDA, Vaccine, Sanofi-Aventis, News

  • Share

Most Recently Shared on August 27, 2010 at 11:34 am By:

Meningitis_News News-Medical.Net

Meningitis News: FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddler... http://bit.ly/doRVE7

2 years ago...

FDA accepts sBLA for Menactra for immunization of infants and toddlers - MPR

empr.com — “Sanofi Pasteur announced that the FDA has accepted for review a supplemental Biologics License Application (sBLA) for the use of Menactra (Meningococcal [Groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on August 26, 2010 at 2:46 pm By:

eMPR MPR Medical Publisher

MPR News: FDA accepts sBLA for Menactra for immunization of infants and toddlers: Sanofi Pasteur announced that th... http://bit.ly/dsE6tE

2 years ago...

FDA accepts sBLA for Menactra for immunization of infants and toddlers - ONA

oncologynurseadvisor.com — “Sanofi Pasteur announced that the FDA has accepted for review a supplemental Biologics License Application (sBLA) for the use of Menactra (Meningococcal [Groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on August 26, 2010 at 2:33 pm By:

Advertisement